StockNews.com assumed coverage on shares of Veradigm (NASDAQ:MDRX - Free Report) in a research report report published on Saturday morning. The brokerage issued a hold rating on the software maker's stock.
Separately, Stephens increased their price objective on shares of Veradigm from $7.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, January 31st.
Check Out Our Latest Stock Report on MDRX
Veradigm Price Performance
NASDAQ MDRX traded up $0.03 during trading hours on Friday, reaching $4.25. The company's stock had a trading volume of 217,141 shares, compared to its average volume of 392,724. The company's 50-day moving average is $4.54 and its two-hundred day moving average is $7.39. Veradigm has a fifty-two week low of $3.80 and a fifty-two week high of $11.80.
About Veradigm
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Featured Articles
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
